NCT01105247 – A Phase 1b/2 Fixed-dose Study of Bruton’s Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia Posted on February 19, 2019 by tsuperadmin -
NCT01236391 – Multicenter Phase 2 Study of Bruton’s Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Relapsed or Refractory Mantle Cell Lymphoma Posted on February 19, 2019 by tsuperadmin -
NCT01722487 – Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Posted on February 19, 2019 by tsuperadmin -
NCT01424930 – An Open-Label Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Subjects With Metastatic Castration-Resistant Prostate Cancer Posted on November 28, 2018 by tsuperadmin -
NCT00924469 – A Phase 2 Open-Label, Randomized, Multi-center Study of Neoadjuvant Abiraterone Acetate (CB7630) Plus Leuprolide Acetate and Prednisone Versus Leuprolide Acetate Alone in Men With Localized High Risk Prostate Cancer Posted on November 28, 2018 by tsuperadmin -
NCT01985126 – An Open-label, Multicenter, Phase 2 Trial Investigating the Efficacy and Safety of Daratumumab in Subjects With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and IMiD) or Are Double Refractory to a Proteasome Inhibitor and an IMiD Posted on March 22, 2018 by tsuperadmin -
Phase II clinical trial of ET-743 as 2nd or 3rd line treatment in patients with advanced stage and/or metastatic soft tissue sarcoma Posted on March 15, 2018 by tsuperadmin -
NCT00796120 – An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS) Posted on March 15, 2018 by tsuperadmin -
NCT00579501 – Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma Posted on March 15, 2018 by tsuperadmin -
Phase 2 study of ET-743 as second or third line therapy in advanced and/or metastatic soft tissue sarcoma patients Posted on March 15, 2018 by tsuperadmin -
The YODA Project